« Return to News | Awards & Advancement

Hagop Kantarjian joins Actinium Pharmaceuticals’ clinical advisory board

Wednesday, October 3, 2012 09:39 AM

Actinium Pharmaceuticals (API), a New York-based biopharmaceutical company focused on immunotherapeutics, has appointed Hagop Kantarjian, MD, to the company's clinical advisory board. 

Kantarjian, who heads the largest leukemia service in the world at MD Anderson Cancer Center in Houston, Texas, will help API in developing its clinical stage drug candidates in the field of hematologic oncology, Actimab-A and Iomab-B, as well as other earlier stage products.

"[Kantarigian] is one of the foremost blood cancer experts in the world and has achieved many esteemed certifications, honors and awards over his career,” said Jack Talley, CEO of Actinium Pharmaceuticals. “Actinium has assembled a superb team of clinical experts to help guide our programs to their next milestones and ultimately expand the number of patients who are successfully in remission for acute myeloid leukemia or able to have a successful bone marrow transplant due to our product candidates."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.